| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.0026 | 1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0026 | 1 |